These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5614 related articles for article (PubMed ID: 3744640)

  • 41. Combined treatment of Lewis lung carcinoma by tumor excision and levan.
    Leibovici J; Michowitz M; Shezen E; Wolman M; Sandbank U
    Oncology; 1981; 38(1):31-4. PubMed ID: 7443174
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of high-molecular levan on the growth and spread of lymphoma in AKR mice.
    Leibovici J; Sinai Y; Wolman M; Davidai G
    Cancer Res; 1975 Aug; 35(8):1921-5. PubMed ID: 1149016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclophosphamide-dependent lymph node modification in lymph node metastasis of MM48 tumor cells in syngeneic mice.
    Yoshida K; Tachibana T
    Jpn J Cancer Res; 1990 Mar; 81(3):253-8. PubMed ID: 2112528
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclophosphamide treatment of an SJL murine B-cell lymphoma increases the proportion of suppressive CD8+ over tumor-stimulatory CD4+ T-lymphocytes.
    Wrone-Smith T; Cankovic M; VanBuren E; Lerman S
    Leuk Res; 1993 Nov; 17(11):967-75. PubMed ID: 8231237
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of macrophages and polymorphs in the levan-induced inhibition of Lewis lung carcinoma in C57BL mice.
    Leibovici J; Borit A; Sandbank U; Wolman M
    Br J Cancer; 1979 Oct; 40(4):597-607. PubMed ID: 497110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
    Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
    Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histological study of homografts showing delayed rejection following levan administration.
    Leibovici J; Wolman M; Bleiberg I
    J Pathol; 1978 Jun; 125(2):103-6. PubMed ID: 363991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of cyclophosphamide treatment on the in vitro activity of mouse lymphoid cells after nonspecific and specific stimulation.
    Snippe H; Davidse RP; Belder M; Willers JM
    Int Arch Allergy Appl Immunol; 1976; 50(5):536-47. PubMed ID: 1083834
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative.
    Limpens J; Van Meijer M; Van Santen HM; Germeraad WT; Hoeben-Schornagel K; Breel M; Scheper RJ; Kraal G
    Immunology; 1991 Jul; 73(3):255-63. PubMed ID: 1879874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipopolysaccharide associated with β-2,6 fructan mediates TLR4-dependent immunomodulatory activity in vitro.
    Young ID; Nepogodiev SA; Black IM; Le Gall G; Wittmann A; Latousakis D; Visnapuu T; Azadi P; Field RA; Juge N; Kawasaki N
    Carbohydr Polym; 2022 Feb; 277():118606. PubMed ID: 34893207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
    Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular mass tumor-associated antigens: the spleen and lymph nodes.
    Ben-Hur H; Kossoy G; Schneider DF; Zandbank J; Zusman I
    Int J Mol Med; 2002 Mar; 9(3):311-6. PubMed ID: 11836638
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increase in cell permeability to a cytotoxic agent by the polysaccharide levan.
    Leibovici J; Stark Y
    Cell Mol Biol; 1985; 31(5):337-41. PubMed ID: 4084938
    [No Abstract]   [Full Text] [Related]  

  • 55. Dietary litchi pulp polysaccharides could enhance immunomodulatory and antioxidant effects in mice.
    Huang F; Zhang R; Liu Y; Xiao J; Liu L; Wei Z; Yi Y; Zhang M; Liu D
    Int J Biol Macromol; 2016 Nov; 92():1067-1073. PubMed ID: 27514443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Positive effect of cyclophosphamide on the expression of MHC class II antigens.
    Marinova-Mutafchieva L; Goranova I; Goranov I
    Methods Find Exp Clin Pharmacol; 1990 Oct; 12(8):545-9. PubMed ID: 2093133
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of L-2-oxothiazolidine-4-carboxylate on the cytotoxic activity and toxicity of cyclophosphamide in mice bearing B16F10 melanoma liver metastases.
    del Olmo M; Alonso-Varona A; Castro B; Calle Y; Bilbao P; Palomares T
    Melanoma Res; 2000 Apr; 10(2):103-12. PubMed ID: 10803710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro stimulation and inhibition of tumor cell growth mediated by different lymphoid cell populations.
    Norbury KC
    Cancer Res; 1977 May; 37(5):1408-15. PubMed ID: 66982
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of cyclophosphamide on mice bearing methylcholanthrene-induced fibrosarcomas.
    Yu S; Lannin DR; Tsui-Collins AL; McKhann CF
    Cancer Res; 1980 Aug; 40(8 Pt 1):2756-61. PubMed ID: 7388826
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 281.